Laser Enucleation System Market Size, Share, and Growth Forecast, 2026 - 2033

The global laser enucleation system market size is likely to be valued at US$0.6 billion in 2026 and is expected to reach US$1.1 billion by 2033, growing at a CAGR of 8.6% between 2026 and 2033.

Market growth is supported by the rising demand for effective benign prostatic hyperplasia (BPH) treatment, increasing adoption of minimally invasive urological procedures, and advances in surgical laser technology. Aging populations, investment in specialized urology services, and demand for durable treatment outcomes are expected to support expansion, although capital costs and surgeon training requirements may limit adoption.

Drivers - Rising Demand for Effective Surgical Treatment of Benign Prostatic Hyperplasia

Benign prostatic hyperplasia is a major indication for laser enucleation systems because prostate enlargement can cause urinary frequency, urgency, weak urine flow, and incomplete bladder emptying. The World Health Organization projects that the global population aged 60 years and older will increase from 1 billion in 2020 to 1.4 billion by 2030. This demographic shift is expected to increase the need for healthcare services addressing age-associated conditions, including urological disorders. Clinical guidance from the American Urological Association recognizes HoLEP and thulium laser enucleation of the prostate (ThuLEP) as prostate-size-independent surgical options for eligible patients with BPH.

These procedures enable surgeons to remove obstructive prostate tissue through an endoscopic approach. Their suitability for different prostate sizes makes them relevant to specialist hospitals treating patients with substantial urinary symptoms. As awareness of available treatment options increases, healthcare providers may expand access to laser-based surgery.

Advances in Laser Technology and Minimally Invasive Urology

Advances in laser energy delivery, fiber design, pulse control, and endoscopic visualization are expanding the technology options available to urologists. Holmium:YAG systems have an established role in prostate enucleation, while thulium fiber lasers provide an alternative platform for selected endoscopic urological procedures. Multifunctional laser platforms can support equipment utilization across approved applications, including urinary stone treatment and certain soft-tissue procedures. Manufacturers are also investing in equipment design and visualization technologies to improve integration into existing surgical workflows.

However, the benefits of a laser system depend on its intended clinical use. Performance in urinary stone lithotripsy does not automatically establish equivalent advantages in prostate enucleation. Clinical evidence, regulatory authorization, surgeon experience, and compatibility with other surgical instruments remain important factors in technology adoption.

Restraints - High Capital Expenditure and the Specialist Learning Curve

Laser enucleation systems require investment in laser generators, compatible endoscopic instruments, optical fibers, maintenance, and staff training. Procedures may also require morcellation equipment, anesthesia services, and appropriate operating-room infrastructure. These requirements can limit adoption at smaller hospitals and facilities with low annual urological surgery volumes. In addition, HoLEP and other enucleation techniques require specialized procedural expertise. The time needed to develop proficiency can affect operating-room efficiency and patient throughput during implementation.

The financial commitment extends beyond the initial equipment purchase. Hospitals must account for consumables, service contracts, equipment downtime, replacement cycles, and training costs. Budget constraints may therefore favor established equipment or alternative surgical techniques.

Opportunities - Expansion of Advanced Urology Services in Asia Pacific

Asia Pacific presents an important growth opportunity as hospitals expand specialist surgical capacity and manufacturers strengthen distribution across China, India, Japan, and Southeast Asia. The region is estimated to account for approximately 38.5% of global revenue under the market assumptions used in this report. Aging populations, investment in tertiary-care facilities, and wider access to specialist consultations may increase demand for advanced BPH procedures.

However, adoption varies according to healthcare spending, reimbursement arrangements, surgeon availability, device registration requirements, and the cost of imported equipment. Large urban hospitals and specialist centers may represent practical entry points because they are more likely to have the infrastructure and patient volumes needed to support advanced laser systems.

Integrated Laser Platforms and Outpatient Treatment Pathways

Multifunctional laser systems create opportunities to serve multiple urological indications through a shared capital platform. Hospitals may evaluate systems for prostate enucleation alongside urinary stone procedures when the equipment is authorized for the intended applications. This approach can improve equipment utilization where clinical demand supports more than one procedure type.

Selected outpatient settings may also offer growth opportunities as healthcare providers evaluate treatment pathways that reduce the need for prolonged hospitalization. However, outpatient suitability depends on patient selection, anesthesia requirements, postoperative monitoring, clinical protocols, and local reimbursement arrangements. Smaller equipment footprints alone do not guarantee adoption by ambulatory surgical centers.

Laser Technology Insights

Holmium laser systems are anticipated to account for approximately 43.6% of the global urology laser market. Their established clinical use, procedural familiarity, and versatility across endourology support demand. For example, Lumenis and Quanta System offer Holmium laser platforms used in urological procedures, including urinary stone treatment. Hospitals also consider surgeon experience, instrument compatibility, maintenance, and consumable costs when selecting systems for BPH surgery.

Thulium fiber laser systems are an emerging technology in endoscopic urology, with applications in urinary stone treatment and selected soft-tissue procedures. For example, Olympus's SOLTIVE SuperPulsed Laser System demonstrates the commercial development of thulium fiber laser technology. Multifunctional capabilities may help hospitals expand their urological services using a shared equipment platform. However, adoption for prostate enucleation depends on procedure-specific clinical evidence, regulatory indications, surgeon training, and compatible instruments.

Procedure Type Insights

HoLEP is anticipated to account for approximately 52.6% of the broader BPH laser therapy market. Its suitability for different prostate sizes and established clinical use support demand. For example, specialist urology centers and tertiary-care hospitals use HoLEP to remove obstructive prostate tissue endoscopically. Adoption depends on trained surgeons, compatible endoscopic instruments, morcellation equipment, and appropriate operating-room infrastructure.

TFL-based prostate enucleation is an emerging procedural opportunity as manufacturers expand thulium fiber laser applications. The segment is projected to grow at a CAGR of 7.12% through 2031 in the U.S. prostate laser surgery market. Olympus's SOLTIVE platform illustrates the development of thulium fiber laser technology in endourology, although its broader applications do not independently establish adoption in prostate enucleation. Growth will depend on clinical outcomes, regulatory indications, surgeon acceptance, equipment costs, and the availability of compatible instruments.

North America Laser Enucleation System Market Trends

North America benefits from established medical-device distribution networks, specialist hospitals, and investment in advanced BPH treatments. The United States is a key market, while Canada offers opportunities through its hospital-based urology services.

United States Laser Enucleation System Market Trends

HoLEP adoption is expanding as more urologists develop procedural expertise. A 2025 study published in the Journal of Endourology found that U.S. HoLEP utilization increased by 52% between 2018 and 2022, while the number of urologists performing the procedure rose from 386 to 451. However, one-third of states still lacked an active HoLEP surgeon, highlighting training and access gaps.

In March 2025, Cook Medical announced the availability of Magneto technology with Quanta System's 100 W and 150 W holmium laser systems, marketed as Cyber Ho in six European countries and Litho in the United States. The technology combines holmium laser capabilities with finer stone-dusting functions and can also benefit HoLEP procedures, strengthening interest in versatile platforms.

Canada Laser Enucleation System Market Trends

Canada's opportunities are linked to specialist urology departments and hospital investment in minimally invasive surgery. Adoption depends on equipment procurement budgets, access to trained surgeons, and maintenance support. Multifunctional laser platforms may appeal to hospitals seeking to serve both prostate surgery and urinary stone treatment, provided the devices are authorized for the intended procedures.

Europe Laser Enucleation System Market Trends

Europe's market outlook is shaped by established healthcare systems, public and private hospital procurement, and regulatory requirements under the European Union Medical Device Regulation. Germany and the United Kingdom are important markets for advanced urological equipment.

Germany Laser Enucleation System Market Trends

Germany's specialist hospitals and medical-technology infrastructure support adoption of laser-assisted BPH procedures. In March 2025, Cook Medical introduced its Magneto-enabled Quanta System holmium laser offering in six European countries under the Cyber Ho brand. The technology supports a broader range of endourological procedures, including HoLEP, potentially increasing the appeal of multifunctional equipment to German hospitals.

United Kingdom Laser Enucleation System Market Trends

The United Kingdom offers opportunities through specialist urology centers and established clinical training networks. Adoption depends on hospital procurement decisions, surgeon availability, and the cost of equipment maintenance. Manufacturers offering compatible instruments, structured training, and reliable servicing can strengthen their position. The expansion of advanced laser platforms also creates opportunities for hospitals to evaluate equipment across multiple authorized urological applications.

Asia Pacific Laser Enucleation System Market Trends

Asia Pacific's anticipated market leadership reflects investment in hospital infrastructure, an aging population, and expanding access to specialist urological care. China, Japan, and India offer distinct opportunities, although affordability, regulatory approvals, and clinical expertise influence adoption.

Japan Laser Enucleation System Market Trends

Japan's aging population and advanced healthcare technology sector support demand for BPH treatment. Olympus's SOLTIVE SuperPulsed Laser System, a thulium fiber laser platform, received Japanese medical-device registration in 2025, according to Japan's Pharmaceuticals and Medical Devices Agency records. The platform supports urinary stone treatment and selected soft-tissue procedures, broadening the available technology options for urology departments. Its impact on enucleation demand depends on the specific authorized applications and clinical adoption.

India Laser Enucleation System Market Trends

India presents opportunities through private tertiary-care hospitals and expanding specialist urology services, although high equipment costs can constrain adoption outside major urban centers. In August 2024, Fortis Hospital and Kidney Institute in Kolkata reported successfully treating a patient with a 290-gram enlarged prostate using HoLEP. This example demonstrates the clinical application of laser enucleation for complex BPH cases and highlights the capabilities available at specialist Indian hospitals. Wider adoption will depend on trained surgeons, equipment affordability, distributor support, and reliable maintenance.

The global laser enucleation system market includes established surgical laser manufacturers, specialist endourology equipment suppliers, and companies developing newer laser platforms. Leading suppliers compete through technology development, clinical support, product reliability, and geographic expansion. Common priorities include improving laser performance, developing compatible instruments, strengthening consumables distribution, and supporting surgeon training. Established suppliers can leverage their installed bases and service networks, while emerging manufacturers may compete through pricing, focused distribution, and differentiated platforms. Lifecycle cost and dependable technical support remain important purchasing considerations.

Key Industry Developments

• In June 2025, Olympus’s SOLTIVE SuperPulsed Laser System entered Japan’s national health insurance reimbursement framework, with coverage taking effect on June 1, 2025, according to Japan’s Ministry of Health, Labour and Welfare.